Canaccord Genuity Reiterates Buy Rating on Tandem Diabetes Care (TNDM) following Type 2 diabetes FDA clearance
Tweet Send to a Friend
Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $63.00 price target on Tandem Diabetes Care (NASDAQ: TNDM) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
